Recruiting
Phase 2

Macupatide & Eloralintide

Sponsor:

Eli Lilly and Company

Code:

NCT07215559

Conditions

Obesity

Overweight

Diabetes Mellitus, Type 2

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Macupatide

Eloralintide

Macupatide Placebo

Eloralintide Placebo

Study Details

Brief summary:

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

Conditions

Obesity

Overweight

Diabetes Mellitus, Type 2

Study ID

NCT07215559

Start date

Oct 16, 2025

Status verified date

Aug, 2026

Completion date

May, 2027

Anticipated

Primary completion date

Mar, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Have type 2 diabetes
  • Have an HbA1c ≥7.5% to ≤10.5% at screening
  • Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening

  • Diet and exercise
  • Stable dose of metformin
  • Sodium-glucose cotransporter-2 (SGLT2) inhibitor
  • Have had a stable body weight (<5% body weight gain and/or loss) for the 3 months prior to screening
  • Have a BMI of 27 or greater at screening

Exclusion Criteria:

  • Have any form of diabetes other than type 2 diabetes
  • Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening
  • Have any of the following cardiovascular conditions within 3 months prior to screening:

  • acute myocardial infarction
  • cerebrovascular accident (stroke)
  • unstable angina, or
  • hospitalization due to congestive heart failure
  • Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include

  • basal or squamous cell skin cancer
  • in situ carcinomas of the cervix, or
  • in situ prostate cancer
  • Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:

  • amylin RA
  • dual amylin and calcitonin RA
  • glucagon-like peptide-1 receptor (GLP-1) RA
  • glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA
  • GLP-1/glucagon (GCG) RAs, or
  • GIP/GLP-1/GCG RAs
  • Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides
  • Have used insulin for diabetic control within the prior year (short term use in certain situations allowed

Study Design

Enrollment

200 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Macupatide (Macupatide + Eloralintide Placebo)

Participants will be administered macupatide subcutaneously (SC) and eloralintide placebo SC

experimental: Eloralintide (Elorlintide + Macupatide Placebo)

Participants will be administered eloralintide SC and macupatide placebo SC

experimental: Macupatide + Eloralintide

Participants will be administered eloralintide SC and macupatide SC

placebo comparator: Placebo (Macupatide Placebo + Elorlintide Placebo)

Participants will be administered eloralintide placebo SC and macupatide placebo SC

Interventions

Macupatide

Administered SC

Eloralintide

Administered SC

Macupatide Placebo

Administered SC

Eloralintide Placebo

Administered SC

Primary outcome measure

  • Percent Change from Baseline in Body Weight [ Time Frame: Baseline, Week 32 ]

Central Contacts and Locations

Central contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

317-615-4559LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Locations

Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC

Recruiting

Gilbert, Arizona, United States, 85296

Contacts

480-691-2213

Principal Investigator:

Sunildat Maheshwari

Synexus Clinical Research US, Inc.

Recruiting

Phoenix, Arizona, United States, 85020

Principal Investigator:

Shawn Searle

Pima Heart

Recruiting

Tucson, Arizona, United States, 85741

Contacts

520329-4139

Principal Investigator:

Paul Bejarano

Precision Clinical Research

Recruiting

Sunrise, Florida, United States, 33351

Principal Investigator:

Jeffrey Schneider

SKY Clinical Research Network Group-Brown

Recruiting

Atlanta, Georgia, United States, 30331

Contacts

888-659-4363

Principal Investigator:

Tamara Brown

Teak Research Consults

Recruiting

Lawrenceville, Georgia, United States, 30043

Principal Investigator:

Kamar Alabi

AGILE Clinical Research Trials, LLC

Recruiting

Sandy Springs, Georgia, United States, 30328

Principal Investigator:

Vasundhara Cheekati

Pivotal Research Solutions

Recruiting

Stonecrest, Georgia, United States, 30038

Contacts

678-825-2887

Principal Investigator:

Rabahuddin Syed

Rophe Adult and Pediatric Medicine/SKYCRNG

Recruiting

Union City, Georgia, United States, 30291

Contacts

470-317-3604

Principal Investigator:

Dwight Blake

Vector Clinical Trials

Recruiting

Las Vegas, Nevada, United States, 89128

Contacts

702-750-0000

Principal Investigator:

Cornell Calinescu

Premier Research

Recruiting

Trenton, New Jersey, United States, 08611

Contacts

609-392-6666

Principal Investigator:

Herbert Conaway

PriMED Clinical Research

Recruiting

Dayton, Ohio, United States, 45429

Contacts

937-534-4201

Principal Investigator:

William Randall

Mercy Family Clinic

Recruiting

Dallas, Texas, United States, 75208

Contacts

281-944-3610

Principal Investigator:

Ebere Israel Azubuike, MD

Velocity Clinical Research, Dallas

Recruiting

Dallas, Texas, United States, 75230

Principal Investigator:

Dan Lender

Biopharma Informatic, LLC

Recruiting

Houston, Texas, United States, 77043

Contacts

281-944-3610

Principal Investigator:

Agadadash Kuliev

PlanIt Research, PLLC

Recruiting

Houston, Texas, United States, 77079

Contacts

713-973-3415

Principal Investigator:

Prashant Koshy

Research Physicians Network, LLC

Recruiting

Houston, Texas, United States, 77089

Contacts

281-944-3610

Principal Investigator:

Jawad Sarwar, MD

Aavon Clinical Trials

Recruiting

Richmond, Texas, United States, 77407

Contacts

713-282-5600

Principal Investigator:

Namrata Dass

Consano Clinical Research, LLC

Recruiting

Shavano Park, Texas, United States, 78231

Contacts

210-545-4900

Principal Investigator:

Michelle Welch

Texas Valley Clinical Research

Recruiting

Weslaco, Texas, United States, 78596

Contacts

956-431-8090

Principal Investigator:

Eduardo Luna

Kalo Clinical Research

Recruiting

West Valley City, Utah, United States, 84120

Contacts

801-363-7353

Principal Investigator:

Cuper Martinez

Eastern Virginia Medical School (EVMS) Medical Group

Recruiting

Norfolk, Virginia, United States, 23510

Contacts

757-446-5291

Principal Investigator:

Elias Siraj

Clinical Research Partners, LLC

Recruiting

Richmond, Virginia, United States, 23226

Contacts

804-477-3045

Principal Investigator:

Robert Call

Northwest Clinical Research Center

Recruiting

Bellevue, Washington, United States, 98007

Principal Investigator:

Jeena Vaid

Rainier Clinical Research Center

Recruiting

Renton, Washington, United States, 98057

Contacts

425-251-1720

Principal Investigator:

Frances Broyles

Universal Research Group

Recruiting

Tacoma, Washington, United States, 98405

Contacts

253-882-1070

Principal Investigator:

Sabrina Benjamin

More Information

Sponsor

Eli Lilly and Company

Last update posted

Aug 21, 2026

Last verified

Aug, 2026

Keywords

  • GIP
  • Amylin

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-08-21.